Sofosbuvir, a nucleotide analog inhibitor of the Hepatitis C RNA-dependent RNA polymerase was recently shown to be protective against Zika virus both in vitro and in vivo.
Researchers believe they may be able to use transchromosomic cattle to rapidly produce human antibodies against other human pathogens as well, in as few as three months.
The dominant type of cholera is naturally resistant to one type of antibiotic usually used as a treatment of last resort.
Researchers compiled antiviral MERS-CoV treatment guidelines based on the 2015 South Korea outbreak response experience of treating patients with MERS in an effort to achieve a more effective MERS treatment in the future.
The return of plague and cholera has revealed a fragile stand-off between humans and bacteria.
Investigators report that a vaccination campaign prevented thousands of cases of Japanese encephalitis and cut infection in Nepal by at least 78 percent.
Increased stability of a plant-produced recombinant protective antigen (rPA) vaccine candidate was achieved in a spray dried powder formulation.
A new study demonstrates that Artemisinin, a malaria treatment which faces issues with an unstable supply, can be rapidly produced by genetically engineering moss.
The treatments were well-tolerated and provided 100 percent protection from Lassa fever.
The US Food and Drug Administration (FDA) has granted accelerated approval to benznidazole for use in children with Chagas disease.